MAM
GLUE icon

Martingale Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Martingale Asset Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$204K Buy
12,424
+11
+0.1% +$210 0.01% 776
2025
Q4 		$195K Buy
+12,413
New +$167K ﹤0.01% 751

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Martingale Asset Management's GLUE Position: Q1 2026 in Review

Martingale Asset Management increased its Monte Rosa Therapeutics (GLUE) stake by 0.09% in Q1 2026, buying an estimated $210 and bringing the position to 12,424 shares worth $204K. The position accounts for 0.01% of the portfolio, ranked #776.

Martingale Asset Management first reported a position in GLUE in Q4 2025 and has held it in 2 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Martingale Asset Management held 12,424 shares of Monte Rosa Therapeutics worth $204K as of Q1 2026.
  • Martingale Asset Management bought 11 Monte Rosa Therapeutics shares in Q1 2026, an estimated $210.
  • Monte Rosa Therapeutics made up 0.01% of Martingale Asset Management's portfolio in Q1 2026, its #776 holding.
  • Martingale Asset Management first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.